Jump to content

EB-002

Add links
From Wikipedia, the free encyclopedia

EB-002
Clinical data
Other namesEB002; EB-373; EB373; Synthetic psilocin prodrug
Routes of
administration		Oral[1]
Drug classNon-selective serotonin receptor agonist; Serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen

EB-002, also formerly known as EB-373, is a synthetic prodrug of the non-selective serotonin receptor agonist and serotonergic psychedelic psilocin which is under development for the treatment of neuropsychiatric disorders like depression and anxiety disorders.[1][2][3][4] It is taken by mouth.[1] The drug is under development by Enveric Biosciences.[1][2][3] As of November 2024, it is in the preclinical research stage of development.[1][2] In November 2024, Enveric Biosciences out-licensed EB-002 to MycoMedica Life Sciences in a deal that was estimated to be worth as much as $62 million.[3] Its exact chemical structure does not yet appear to have been disclosed.[1]

See also

[edit]

References

[edit]
  1. ^ a b c d e f "Enveric Biosciences". AdisInsight. 22 November 2024. Retrieved 16 February 2025.
  2. ^ a b c "Delving into the Latest Updates on EB-373 with Synapse". Synapse. 25 January 2025. Retrieved 16 February 2025.
  3. ^ a b c Jackson A (12 November 2024). "Enveric inks $62M licensing deal for psilocin prodrug". Green Market Report. Retrieved 16 February 2025.
  4. ^ "Investigational Psilocin Prodrug Gains Patent Protection for Sleep Disorder Applications". Sleep Review. 18 July 2024. Retrieved 16 February 2025.
[edit]



Stub icon

This hallucinogen-related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=EB-002&oldid=1275993179"